Education
About Us
Working with TipRanks
Follow Us
Precigen, Inc. (PGEN)
NASDAQ:PGEN
PGEN Stock Chart & Stats
$4.74
-$0.11(-8.33%)
At close: 4:00 PM EST
$4.74
-$0.11(-8.33%)
Day’s Range― - ―
52-Week Range$1.11 - $5.47
Previous CloseN/A
Volume729.99K
Average Volume (3M)4.46M
Market Cap
$1.19B
Enterprise Value$1.10B
Total Cash (Recent Filing)$121.14M
Total Debt (Recent Filing)$98.19M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 09, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding353,824,500
10 Day Avg. Volume5,874,050
30 Day Avg. Volume4,455,367
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)7.79
Price to Sales (P/S)76.40
P/FCF Ratio-3.91
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue173.77
Enterprise Value/Gross Profit756.08
Enterprise Value/Ebitda-4.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$98.61M
Bulls Say, Bears Say
Bulls Say
FDA Approval & Clinical EfficacyFull FDA approval for Papcemias transforms Precigen from a pure R&D biotech into a commercial-stage company for RRP. As a first‑and‑only therapy with strong clinical results, it durablely reduces regulatory risk, enables revenue generation, and supports long-term commercial investment and market entry.
Rapid Commercial Traction & Payer CoverageQuick institutional engagement and broad payer coverage indicate strong product adoption and reimbursement groundwork. These durable sales and access achievements increase likelihood of sustained uptake, predictable revenue streams, and faster scaling of commercial operations across regions and patient cohorts.
In‑house Manufacturing CapabilityOwning an FDA‑inspected cGMP facility gives durable control over supply, quality, and unit economics as demand grows. This reduces reliance on external CDMOs, shortens time to supply scale‑up, and supports gross margin improvement and timely launches of follow-on indications or geographies.
Bears Say
Large Ongoing Cash BurnSustained negative operating and free cash flow requires continued external financing or material profitable ramp from product sales. Over multiple quarters this elevates dilution or refinancing risk, constrains strategic flexibility, and pressures ability to fund R&D and commercial expansion without additional capital.
Materially Higher LeverageA sharp increase in leverage materially raises fixed obligations and interest exposure, reducing balance sheet resilience. Higher debt limits strategic options, increases refinancing risk if revenues lag, and makes the company more vulnerable to operational setbacks during commercialization.
Persistent Unprofitability & Weak Operating MarginsDespite revenue growth, large negative operating margins show weak profit conversion and heavy cost structure. Sustained unprofitability means long runway required to reach self‑funding, and continued high SG&A for commercialization could pressure margins absent durable sales scale and efficiency gains.
Precigen News
PGEN FAQ
What was Precigen, Inc.’s price range in the past 12 months?
Precigen, Inc. lowest stock price was $1.11 and its highest was $5.46 in the past 12 months.
What is Precigen, Inc.’s market cap?
Precigen, Inc.’s market cap is $1.19B.
When is Precigen, Inc.’s upcoming earnings report date?
Precigen, Inc.’s upcoming earnings report date is Mar 09, 2026 which is in 2 days.
How were Precigen, Inc.’s earnings last quarter?
Precigen, Inc. released its earnings results on Nov 13, 2025. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.966.
Is Precigen, Inc. overvalued?
According to Wall Street analysts Precigen, Inc.’s price is currently Overvalued.
Does Precigen, Inc. pay dividends?
Precigen, Inc. does not currently pay dividends.
What is Precigen, Inc.’s EPS estimate?
Precigen, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Precigen, Inc. have?
Precigen, Inc. has 353,824,500 shares outstanding.
What happened to Precigen, Inc.’s price movement after its last earnings report?
Precigen, Inc. reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went up 25.648%.
Which hedge fund is a major shareholder of Precigen, Inc.?
Currently, no hedge funds are holding shares in PGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precigen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PGEN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.61%
12-Months-Change
Fundamentals
Return on Equity
-507.72%
Trailing 12-Months
Asset Growth
105.17%
Trailing 12-Months
Company Description
Precigen, Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
PGEN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was optimistic, highlighting the transformative approval and rapid deployment of Papcemias, along with strong financial positioning and manufacturing capabilities. Despite increased expenses, the company anticipates reaching cash flow breakeven by 2026.View all PGEN earnings summariesTechnical Analysis
MiMedx Group
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Immunome
―
Praxis Precision Medicines
―
Ownership Overview
37.16% Insiders
11.21% Mutual Funds
9.89% Other Institutional Investors
33.88% Public Companies and
Individual Investors